SRR1475022
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.468
- COAGULATION+0.423
- PANCREAS_BETA_CELLS+0.342
- MYOGENESIS+0.297
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.249
- ESTROGEN_RESPONSE_LATE+0.181
- BILE_ACID_METABOLISM+0.167
- XENOBIOTIC_METABOLISM+0.165
- TNFA_SIGNALING_VIA_NFKB+0.154
- INFLAMMATORY_RESPONSE+0.151
Top 10 suppressed
- MYC_TARGETS_V1-0.604
- PROTEIN_SECRETION-0.546
- UNFOLDED_PROTEIN_RESPONSE-0.475
- DNA_REPAIR-0.464
- E2F_TARGETS-0.453
- MTORC1_SIGNALING-0.451
- MYC_TARGETS_V2-0.444
- OXIDATIVE_PHOSPHORYLATION-0.405
- ANDROGEN_RESPONSE-0.393
- G2M_CHECKPOINT-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1392725 | GTEX | — | 0.971 |
| 2 | SRR1432765 | GTEX | — | 0.958 |
| 3 | SRR1330346 | GTEX | — | 0.953 |
| 4 | SRR1455698 | GTEX | — | 0.953 |
| 5 | SRR1415732 | GTEX | — | 0.950 |
| 6 | SRR1455305 | GTEX | — | 0.943 |
| 7 | SRR1418604 | GTEX | — | 0.941 |
| 8 | SRR1457551 | GTEX | — | 0.941 |
| 9 | SRR1444559 | GTEX | — | 0.938 |
| 10 | SRR1500617 | GTEX | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.468 | Remibrutinib | — uncovered |
| COAGULATION | 0.423 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.342 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.297 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.249 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.181 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.167 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.165 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.154 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.151 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.133 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.114 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.103 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.051 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.051 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.047 | Idelalisib | — uncovered |
| HYPOXIA | 0.043 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.027 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.010 | Idelalisib | — uncovered |